Q-linea AB (publ), a company listed on Nasdaq Stockholm that develops and delivers innovative solutions for the diagnosis of infectious diseases, has carried out a directed issue of shares raising the company gross proceeds of SEK 301 million. ABG Sundal Collier, Carnegie Investment Bank and Kempen & Co acted Joint Bookrunners in connection with the directed issue.
The subscription price was determined through an accelerated book building procedure to SEK 137 per share, which corresponds to a discount of approximately 5.8 percent in relation to the closing price on Nasdaq Stockholm on June 10, 2021. A number of Swedish and international institutional investors and sector specialist investors participated in the directed issue.
Lindahl's team consisted of Mattias Prage (responsible partner), Helena Lindbäck and Elsa Malmqvist.
